Aerosol Nanoencapsulation: Single-Pass Floating Self-Assembly of Biofunctional Hybrid Nanoplatforms
Source abstract
Abstract
Multifunctional nanoplatforms were prepared via floating self-assembly using a hard nanoparticle (NP) as the core and a modified-polymer (MP, cholesterol-chitosan linked with polyethylenimine) droplet as the shell in a single-pass aerosol nanoencapsulation process. The floating hard NPs (silica, calcium carbonate, gold-decorated graphene oxide, and thiol-capped gold) were directly injected into MP droplets at the opening of a spraying device. Subsequently, the solvent was thermally extracted from the droplets, resulting in the formation of biofunctional nanoplatforms. Measured in vitro, the genes complexed with the nanoplatforms were transfected into target cells, exhibiting higher efficiencies for the MP particles alone without a significant increase in in vitro cell cytotoxicity. The aerosol encapsulation could be further extended to prepare other combinations [gold-silica and gold-calcium carbonate including doxorubicin (Dox)] using the MP, and their hybrid natures demonstrated photothermal cancer cell killing and chemo-thermal Dox release capabilities through surface plasmon resonance heating.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrohydrodynamics and Fluid Dynamics · Electrospun Nanofibers in Biomedical Applications · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Mechanical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea
Funding
National Research Foundation of Korea
References (30)
Show source-provided references
1. 10.1038/nmat244210.1038/nmat2442 ↗
2. 10.1166/jnn.2011.415610.1166/jnn.2011.4156 ↗
3. 10.1002/adma.20070318310.1002/adma.200703183 ↗
4. 10.1021/ar800035u10.1021/ar800035u ↗
5. 10.1517/17425247.2010.51460410.1517/17425247.2010.514604 ↗
6. 10.1021/la703775a10.1021/la703775a ↗
7. 10.1021/bc900479810.1021/bc9004798 ↗
8. 10.1002/adfm.20080184410.1002/adfm.200801844 ↗
9. 10.1002/mabi.20100028310.1002/mabi.201000283 ↗
10. 10.1002/adma.20070219310.1002/adma.200702193 ↗
11. 10.1142/S0219581X0400253X10.1142/S0219581X0400253X ↗
12. 10.1021/jp108828c10.1021/jp108828c ↗
13. 10.1002/smll.20160102310.1002/smll.201601023 ↗
14. 10.1002/mabi.20060025810.1002/mabi.200600258 ↗
15. 10.1211/jpp.61.11.001610.1211/jpp.61.11.0016 ↗
16. 10.1002/adma.20100141010.1002/adma.201001410 ↗
17. 10.1146/annurev.bioeng.4.100101.13231110.1146/annurev.bioeng.4.100101.132311 ↗
18. 10.1021/cm903348410.1021/cm9033484 ↗
19. 10.1021/ja902039y10.1021/ja902039y ↗
20. 10.1021/nl015662g10.1021/nl015662g ↗
21. 10.1021/cm011061e10.1021/cm011061e ↗
22. 10.1016/j.ijpharm.2011.10.01310.1016/j.ijpharm.2011.10.013 ↗
23. 10.1016/j.vaccine.2010.10.00110.1016/j.vaccine.2010.10.001 ↗
24. 10.1039/c4tb00271g10.1039/c4tb00271g ↗
25. 10.1002/smll.20110019110.1002/smll.201100191 ↗
26. 10.1039/b816886e10.1039/b816886e ↗
27. 10.1021/am501069u10.1021/am501069u ↗
28. 10.1002/app.2063010.1002/app.20630 ↗
29. 10.1098/rsif.2009.002110.1098/rsif.2009.0021 ↗
30. 10.1002/smll.20070059510.1002/smll.200700595 ↗